Throwing the kitchen sink at melanoma drug development

Pigment Cell and Melanoma Research

Volumn 25, Issue 5, 2012, Pages 543-544

  Flaherty, Keith T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; CASPASE 8; DOXORUBICIN; ERLOTINIB; GUANINE NUCLEOTIDE BINDING PROTEIN; HEAT SHOCK PROTEIN 90; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN TYROSINE KINASE;

BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; CELL CYCLE; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DNA MODIFICATION; DRUG EFFICACY; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; MELANOMA; NOTE; ONCOGENE; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84865565335     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2012.01038.x     Document Type: Note

References (5)

1. Berger, M.F., Hodis, E., Heffernan, T.P. et al. (2012). Melanoma genome seque-ncing reveals frequent PREX2 mutations. Nature 485, 502-506.
2. Flaherty, K.T., Hodi, F.S., and Fisher, D.E. (2012). From genes to drugs: targeted strategies for melanoma. Nat. Rev. Cancer 12, 349-361.
3. Lee, M.J., Ye, A.S., Gardino, A.K. et al. (2012). Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794.
4. Weber, J.S., Flaherty, K.T., Infante, J.R. et al. (2012). Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. J. Clin. Oncol. 30, suppl; abstr 8510.
5. Wei, X., Walia, V., Lin, J.C. et al. (2011). Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442-446.